STOCK TITAN

Tarsus (TARS) director awarded RSUs and options for 6,254 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tarsus Pharmaceuticals director Andrew D. Goldberg received new equity awards as part of his compensation for serving as a non-employee director. He was granted 2,417 Restricted Stock Units, each representing a contingent right to receive one share of Tarsus common stock. He also received a stock option covering 3,837 shares of common stock at an exercise price of $64.34 per share. Both the RSUs and the option were granted in connection with the company’s 2026 annual meeting of stockholders and will vest in full on the one-year anniversary of the grant date, subject to his continuous board service.

Positive

  • None.

Negative

  • None.
Insider Goldberg Andrew D.
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 3,837 $0.00 --
Grant/Award Restricted Stock Units 2,417 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 3,837 shares (Direct, null); Restricted Stock Units — 2,417 shares (Direct, null)
Footnotes (1)
  1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
Restricted Stock Units granted 2,417 units Equity award for non-employee director service
Stock options granted 3,837 options Annual option grant for director service
Option exercise price $64.34 per share Stock Option (right to buy) grant
Option expiration date June 24, 2036 Expiration for director stock option grant
RSUs underlying shares 2,417 shares Each RSU equals one Tarsus common share
Options underlying shares 3,837 shares Shares subject to director stock option
Restricted Stock Units financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (right to buy financial
"Stock Option (right to buy) with an exercise price of $64.34 per share"
non-employee director financial
"granted in connection with the Reporting Person's service as a non-employee director"
annual meeting of stockholders financial
"as of the Company's 2026 annual meeting of stockholders"
vest in full financial
"The option will vest in full on the one-year anniversary of the date of grant"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Goldberg Andrew D.

(Last)(First)(Middle)
C/O TARSUS PHARMACEUTICALS, INC.
17700 LAGUNA CANYON ROAD, FLOOR 4

(Street)
IRVINE CALIFORNIA 92618

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$64.3406/25/2026A3,837 (1)06/24/2036Common Stock3,837$03,837D
Restricted Stock Units(2)06/25/2026A2,417 (3) (3)Common Stock2,417$02,417D
Explanation of Responses:
1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
3. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
Remarks:
/s/ Scott Sieckert, Attorney-in-Fact06/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Tarsus (TARS) report for Andrew D. Goldberg?

Tarsus reported an equity compensation grant to director Andrew D. Goldberg. He received 2,417 Restricted Stock Units and a stock option for 3,837 shares, both tied to his service as a non-employee director following the company’s 2026 annual meeting of stockholders.

How many Restricted Stock Units were granted to the Tarsus director?

Andrew D. Goldberg was granted 2,417 Restricted Stock Units. Each RSU represents a contingent right to receive one share of Tarsus common stock, subject to vesting conditions linked to his continued service as a non-employee director on the company’s board.

What stock options did Andrew D. Goldberg receive from Tarsus (TARS)?

He received a stock option covering 3,837 shares of Tarsus common stock. The option has an exercise price of $64.34 per share and was granted as an annual option in connection with his service as a non-employee director.

When do the new Tarsus RSUs and options for Andrew D. Goldberg vest?

Both the RSUs and the stock option vest in full one year after grant. Vesting occurs on the one-year anniversary of the grant date, provided Goldberg continues to serve as a non-employee director throughout that period on Tarsus’s board.

Is Andrew D. Goldberg’s Form 4 transaction a market buy or sell of Tarsus stock?

No, the Form 4 reflects equity compensation grants, not market trades. The transactions are awards of Restricted Stock Units and stock options for board service, rather than open-market purchases or sales of Tarsus common shares.

What is the exercise price and expiration for the new Tarsus stock option grant?

The stock option has a $64.34 per share exercise price and expires in 2036. Specifically, it carries an exercise price of $64.34 and an expiration date of June 24, 2036, assuming it remains outstanding and unexercised until then.